Serine hydroxymethyltransferase 2 (SHMT2) regulates one-carbon transfer reactions that are essential for amino acid and nucleotide metabolism, and uses pyridoxal-5′-phosphate (PLP) as a cofactor. Apo SHMT2 exists as a dimer with unknown functions, whereas PLP binding stabilizes the active tetrameric state. SHMT2 also promotes inflammatory cytokine signalling by interacting with the deubiquitylating BRCC36 isopeptidase complex (BRISC), although it is unclear whether this function relates to metabolism. Here we present the cryo-electron microscopy structure of the human BRISC-SHMT2 complex at a resolution of 3.8 Å. BRISC is a U-shaped dimer of four subunits, and SHMT2 sterically blocks the BRCC36 active site and inhibits deubiquitylase activity. Only the inactive SHMT2 dimer-and not the active PLP-bound tetramer-binds and inhibits BRISC. Mutations in BRISC that disrupt SHMT2 binding impair type I interferon signalling in response to inflammatory stimuli. Intracellular levels of PLP regulate the interaction between BRISC and SHMT2, as well as inflammatory cytokine responses. These data reveal a mechanism in which metabolites regulate deubiquitylase activity and inflammatory signalling.
SHMT2 functions in one-carbon folate metabolism that supports the purine and thymine synthesis that is required for cell growth and proliferation. Full-length SHMT2 localizes to mitochondria through an N-terminal mitochondria-targeting sequence; an N-terminal truncation that removes residues 1-21 generates the cytoplasmic SHMT2α isoform 1,2 ( Fig. 1a) . PLP, the active form of vitamin B6, promotes a shift in the SHMT2 oligomeric state from an inactive dimer to the enzymatically active tetramer 1, 3 . SHMT2 also controls inflammatory cytokine signalling through its interaction with the BRISC deubiquitylase (DUB). BRCC36 is a JAMM (JAB1, MOV34, and MPR1, PAD1 N-terminal (MPN) family) Zn 2+ -dependent DUB and functions within two macromolecular complexes, which requires interaction with MPN -pseudo-DUBs Abraxas 1 or Abraxas 2 for DUB activity [4] [5] [6] (Fig. 1a) . The nuclear Abraxas 1 isopeptidase complex (ARISC) complex partners with RAP80 and BRCA1, and forms the BRCA1-A complex that is required for DNA repair [7] [8] [9] [10] . Direct interaction with SHMT2 enhances the delivery of BRISC to ubiquitylated type I interferon (IFN) receptors (IFNAR1 and IFNAR2) 11, 12 , which allows BRCC36 to deubiquitylate the lysine-63-linked ubiquitin chains (Ub(K63)) on IFNAR1 and IFNAR2 and limits the endocytosis and lysosomal degradation of these receptors 12 . BRISCdeficient mice exhibit attenuated IFN responses and are protected from pathological conditions that stem from increased levels of inflammatory signalling 12 . The association between BRISC and SHMT2 therefore provides a potential link between metabolism and inflammation.
The BRCC36-Abraxas 2 complex is an obligate dimer of heterodimers that is essential for DUB activity and IFN signalling 13, 14 . Similarly, BRISC and ARISC are active as stable dimers of tetramers with stoichiometry 2:2:2:2 (refs 4, 5, 13, 15 ). Structures of the human BRISC are currently unavailable, and the molecular basis for SHMT2 binding and regulation is unknown. We present the cryo-electron microscopy (cryo-EM) structure of the BRISC-SHMT2 complex at a resolution of 3.8 Å, which reveals the BRISC architecture and the molecular basis of the inhibition of DUB activity by SHMT2. Structure-guided mutations or increasing intracellular levels of PLP reduced the interaction between BRISC and SHMT2 as well as inflammatory signalling, which reveals a direct link between vitamin B6 metabolism and control of immune responses.
SHMT2 is an endogenous BRISC inhibitor
We produced SHMT2ΔN (residues 18-504), which lacks the mitochondria-targeting sequence and is a mixture of dimers and tetramers in solution (Fig. 1b) . Tetramer peak fractions absorbed strongly at 435 nm, which indicates association with PLP and is consistent with previous findings that PLP binding promotes a shift from an inactive dimer to the active SHMT2 tetramer 1 (Fig. 1c , Extended Data Fig. 1a, b ). Dimer and tetramer peaks were confirmed by native mass spectrometry (Extended Data Fig. 1c) .
A serendipitous SHMT2(A285T) substitution near the PLP-acceptor residue (K280) was identified by the Structural Genomics Consortium (RCSB Protein Data Bank (PDB) code 6DK3). SHMT2ΔN(A285T) is dimeric in solution and crystal lattice, which enables a direct comparison between dimer (apo enzyme) and tetramer (holoenzyme) structures (Extended Data Fig. 1a-d) . Structures of individual wildtype SHMT2α and SHMT2ΔN(A285T) protomers are similar, which suggests that the A285T substitution does not substantially perturb the structure (Extended Data Fig. 1e ). However, the A285T substitution reduces covalent PLP association, subsequent tetramerization and catalytic activity (Extended Data Fig. 2a, b ). The addition of PLP induced a transition from the dimer to the tetramer form of SHMT2ΔN, which led to a large shift in thermal melting temperature (Extended Data Fig. 2c, d ). This shift was largely reduced or abolished Article reSeArcH in SHMT2(A285T) and SHMT2(K280A) mutants, which is consistent with studies that show that alterations of SHMT2 that abrogate PLP binding shift the equilibrium towards the dimer 1,16-19 (Extended Data  Fig. 2e ).
The addition of SHMT2ΔN inhibited the DUB activity of BRISC (Fig. 1d) . Dimeric SHMT2ΔN was a better inhibitor (half maximal inhibitory concentration (IC 50 ) = 9 nM) than the tetrameric form (IC 50 = 77.5 nM). Because the SHMT2ΔN tetramer is not fully saturated with PLP (Extended Data Fig. 2c, d ), preincubation with PLP further reduced BRISC inhibition by the SHMT2ΔN tetramer (Fig. 1d) . The obligate dimers SHMT2ΔN(A285T) and SHMT2ΔN(K280A/ A285T) were effective inhibitors of BRISC and similar to SHMT2ΔN dimers (Fig. 1d) . SHMT2ΔN(A285T) DUB inhibition was selective for BRISC as compared to ARISC (Fig. 1e) , which confirms that SHMT2 does not interact with the ARISC 12 . These data suggest a previously unknown role for the dimeric (PLP-free) form of SHMT2 in regulating the DUB activity of BRISC.
Structure of the BRISC-SHMT2 complex
To understand the molecular basis of the BRISC-SHMT2 association, and how PLP-dependent SHMT2 oligomerization affects DUB activity, we solved the structure of the BRISC bound to an SHMT2 dimer. Using limited proteolysis, we identified a minimal complex-which we term BRISCΔNΔC (Extended Data Fig. 3a, b) -that contains BRCC36, BRCC45, MERIT40ΔN (residues 72-329) and Abraxas 2ΔC (residues 1-267). BRISC and BRISCΔNΔC were active towards a fluorogenic K63-linked diubiquitin (diUb) substrate (Extended Data Fig. 3c ) and both were inhibited by SHMT2ΔN(A285T), with similar IC 50 values (Extended Data Fig. 3d ). SHMT2ΔN(A285T) formed a stable equimolar complex with BRISCΔNΔC (Extended Data Fig. 3e, f) .
We used negative-stain electron microscopy and single-particle cryo-EM to evaluate BRISCΔNΔC and the BRISCΔNΔC-SHMT2ΔN(A285T) complex. BRISCΔNΔC particles showed distinct U-shaped assemblies that were similar to those seen for the nuclear ARISC 15 . However, BRISCΔNΔC showed heterogeneity and flexibility of the 'arm' regions (Extended Data Fig. 4a ). The BRISCΔNΔC-SHMT2ΔN(A285T) complex was homogeneous, with SHMT2ΔN(A285T) bridging both arms of the U-shaped BRISC structure in two-dimensional class averages (Extended Data Fig. 4a ). We collected a large cryo-EM dataset and identified 71,262 particles (approximately 11%) with a structure with apparent C2 symmetry that contained a central trapezoidal region and two extending arms. The remaining particles form a structure that is missing one arm (Extended Data Fig. 4b, c) . After three-dimensional classification and refinement, using both C1 and C2 symmetry, we obtained electron microscopy density maps at resolutions of 3.8 Å and 4.2 Å, respectively (Extended Data Fig. 4c, d , Extended Data Table 1) .
The BRISCΔNΔC comprises a central core region and two extending arms. We fit the structure of insect BRCC36-Abraxas 2 (PDB code 5CW3) 13 at the base of the map; the quality of the electron microscopy density in this region was sufficient for modelling the human BRCC36-Abraxas 2 sequence into the structure (Fig. 2) . The SHMT2ΔN(A285T) dimer was immediately recognizable in the electron microscopy map, with the structure (PDB code 6DK3) fitting directly above the MPN domains of BRCC36-Abraxas 2 (Fig. 2) . The remaining unoccupied Article reSeArcH density belongs to BRCC45 and MERIT40, for which no experimental structures are available.
BRCC45 contains two ubiquitin E2 variant (UEV) domains at its N and C termini. We used the FFAS03 20 and HHpred 21 algorithms to search for additional domains and identified a putative 'UBC-like' domain within residues 144-280, which suggests the presence of a middle UEV domain (UEV-M). Tandemly repeated domains are common during protein evolution, which provides reinforcement for the independent prediction of a third UEV domain in BRCC45 (ref.
22
) (Fig. 1a) . Consistent with this hypothesis, we manually built a Cα-backbone structure for two consecutive UEV domains of BRCC45 into the density that immediately extends from Abraxas 2 (Fig. 2a) . However, owing to the low resolution of this region, precise assignment of the sequence was not possible.
We used the structure of the related ARISC 15 as a guide to place homology models of MERIT40 and a third UEV (BRCC45) domain within the 'fist-like' density in the distal region of each arm (Fig. 2a) . The resolution in this peripheral region is poor (approximately 10 Å), and it was therefore not possible to ascertain the precise orientation of the von Willebrand factor type A (vWFA) and UEV-C domains of MERIT40 and BRCC45, respectively. We modelled UEV-N and UEV-C in proximity to Abraxas 2 and MERIT40, respectively, in accordance with previous deletion studies 4, 23 (Fig. 2a) . Thus, we built a complete BRISC-SHMT2 model using a combination of known structures, de novo model building and homology modelling (Fig. 2a) . The 'core' structure-consisting of the BRCC36-Abraxas 2 superdimer and the SHMT2 obligate dimer-is well-resolved, with a local resolution of 3.5-4.0 Å (Extended Data Figs. 4c, d, 5a, b) .
SHMT2 bridges the two arms of the BRISC and sits directly above the BRCC36-Abraxas 2 superdimer, which explains the requirement for superdimer formation in SHMT2 binding 13 . SHMT2 interacts with MPN domains of BRCC36 and Abraxas 2, and UEV-N and UEV-M domains of BRCC45 (Fig. 2a) . The main BRISC-interacting surface on SHMT2 is centred on the two α6 helices; proximal residues between SHMT2-Abraxas 2, SHMT2-BRCC36 and Abraxas 2-BRCC45 are shown in Fig. 2b . MERIT40 does not contact SHMT2 directly (Fig. 2a) , and its position may provide stabilizing interactions with BRCC45 while also interacting with other signalling molecules 24 . A comparison between human and insect BRCC36-Abraxas 2 superdimers reveals a similar overall structure, with minor local differences (Extended Data Fig. 5c-e) . Overall, the structure provides a view of the interaction surfaces between SHMT2 and components of the BRISC.
Previous work suggested that the BRISC also interacts with SHMT1 in cells, although cellular BRISC-SHMT2 complexes were much more abundant 12 . To test whether SHMT2 and SHMT1 interact equally with BRISC in vitro, we purified SHMT1 dimers and tetramers; we failed to assemble BRISC-SHMT1 complexes and observed no inhibition of BRISC DUB activity in vitro (Extended Data Fig. 6 ). Although it remains possible that BRISC-SHMT1 complexes form in cells, we predict these will be of lower affinity in comparison with BRISC-SHMT2 complexes, and may be a consequence of indirect interactions with other factors.
We altered SHMT2 residues in proximity to BRISC (Fig. 2b) , and assessed their effects on DUB activity in vitro. Residue substitutions were made in the SHMT2ΔN(A285T) background, which purifies as a dimer (Extended Data Fig. 7a, b) . SHMT2ΔN(A285T) variants containing L211R or L215R were each less-potent inhibitors of BRISC DUB activity as compared to SHMT2ΔN(A285T), and the SHMT2ΔN(A285T/L211R/L215R) mutant had no detectable inhibitory effect on BRISC activity (Extended Data Fig. 7c ). SHMT2ΔN inhibition was also observed with hexa-ubiquitin (hexaUb) chains as substrates (Extended Data Fig. 7d ). DUB activity was only marginally reduced when assayed with SHMT2ΔN(A285T/L211R/L215R), SHMT2ΔN tetramers or SHMT1, which mirrors results obtained with fluorescently labelled diUb and is consistent with the observation that the L211R/L215R double substitution reduces BRISC-SHMT2 interaction in vitro (Extended Data Fig. 8a ). These experiments establish the SHMT2 α6 helix as the most important contact surface for BRISC interaction and inhibition of DUB activity.
BRISC-SHMT2 affects immune signalling
To understand the relevance of the BRISC-SHMT2 interaction in cells, we altered interface residues between SHMT2, Abraxas 2 and BRCC45 ( Fig. 2b) and assessed interactions by co-immunoprecipitation (Fig. 3a,  b) . Consistent with the loss of interaction with SHMT2, the Abraxas 2 mutants A142R, E144A and E144R expressed in Abraxas2 -/-mouse embryonic fibroblasts (MEFs) showed reduced STAT1 phosphorylation in response to infection with herpes simplex virus (HSV); this was also true for N100R, Y107R and D23R mutants, which either reduce or prevent BRCC45-MERIT40 binding (Fig. 3c) . The BRISC-SHMT2 interaction was also required for immune signalling when cells were challenged using lipopolysaccharide (LPS) or IFNβ (Fig. 3d) . Moreover, we observed increased IFNAR1 ubiquitylation after IFN stimulation in cells that overexpressed the Abraxas 2 E144R mutant (Extended Data  Fig. 7e) .
For a broader view of immune signalling output that is dependent on the BRISC-SHMT2 complex, we performed quantitative PCR with reverse transcription (qRT-PCR) analysis of 79 genes that are often upregulated during a type I interferon response. Ectopic expression of wild-type Abraxas 2 resulted in 48 genes being upregulated between 2-and 8,000-fold in response to LPS (Fig. 3e, Extended Data Fig. 9a) . Accordingly, LPS challenge of Abraxas2 -/-cells or Abraxas2 -/-cells ectopically expressing Abraxas 2(E144R) showed a poor response, with 11 and 8 genes, respectively, being upregulated between two-and tenfold compared to non-challenged Abraxas2 -/-cells (Fig. 3e) . We next altered SHMT2 residues to ascertain their importance in cellular assembly of BRISC-SHMT2 complexes. Overexpression of SHMT2ΔN(L211R/L215R) resulted in the loss of BRISC-SHMT2 interaction in MEFs, which mirrors the results seen in vitro (Extended Data Figs. 7f, 8a) . Levels of STAT1 phosphorylation were also affected in cells that were challenged with LPS (Extended Data Fig. 7g ), and we observed increased IFNAR1 ubiquitylation after IFN stimulation of cells that overexpress the SHMT2ΔN(L211R/L215R) mutant (Extended Data Fig. 7e ). Collectively, these findings reveal the specific Abraxas 2 and SHMT2 surfaces that are required for BRISC-SHMT2 complex assembly and immune signalling in cells.
The positioning of SHMT2 within the structure provides a potential rationale for its inhibition of DUB activity, as it blocks the BRCC36 active site (Extended Data Fig. 8b ). Kinetic data suggest SHMT2 acts as an apparent competitive inhibitor (Extended Data Fig. 8c) . However, the increase in K m was only moderate (about twofold at equimolar BRISC-SHMT2 complex), which suggests that Ub(K63) chains might displace bound SHMT2 from BRISC when polyubiquitylated substrates are in close proximity. This model would account for the counterintuitive function of SHMT2 as both an inhibitor of BRISC activity and an essential mediator of BRISC association with sites of DUB action (Extended Data Fig. 10) . It is also possible that other factors and post-translational modifications trigger SHMT2 dissociation from BRISC in cells. We propose that SHMT2 acts as a reversible endogenous BRISC inhibitor that prevents non-specific DUB activity. This regulated safety mechanism is similar in concept to protease inhibition by endogenous inhibitors 25 . To our knowledge, SHMT2 is the first example of an endogenous DUB inhibitor, which acts as a precedent for the possible regulation of other DUBs in vivo.
Regulation of BRISC-SHMT2 interaction by PLP
BRISC DUB inhibition provides the first non-enzymatic role of the SHMT2 dimer. Our structure explains why the apo SHMT2 dimerbut not the PLP-bound tetramer-inhibits DUB activity. The SHMT2 α6 helix interacts with BRISC, and this interaction interface overlaps with the SHMT2 tetramerization surface; this accounts for the observation that the SHMT2 tetramer and the BRISC-SHMT2 complexes are mutually exclusive (Extended Data Figs. 1b, 8d ). The SHMT2ΔN-PLP tetramer does not form BRISC-SHMT2 complexes in vitro (Extended Data Fig. 8e ), which suggests that PLP-induced tetramerization could Article reSeArcH regulate SHMT2 dimer availability and BRISC-SHMT2 complex formation in cells.
To test this hypothesis, we cultured MEFs and HEK293T cells in B6-vitamer-free medium, and compared the BRISC-SHMT2 interaction after pyridoxal supplementation (Fig. 4a) . PLP levels were confirmed by vitamin B6 metabolite measurements in whole-cell lysates (Fig. 4b) , and fewer SHMT2 dimers were present after pyridoxal supplementation (Extended Data Fig. 9b ). This coincided with a marked reduction of overexpressed SHMT2ΔN and endogenous Abraxas 2 interaction (Fig. 4a) . Similarly, the interaction between overexpressed Abraxas 2 and endogenous SHMT2 was reduced (Fig. 4c) . The PLPdependent reduction of BRISC-SHMT2 interaction was not observed when PLP-resistant SHMT2 mutants were expressed (Fig. 4d) .
We next measured levels of STAT1 phosphorylation, and observed a pyridoxal-dependent reduction of phosphorylated STAT1 upon IFNβ stimulation ( Fig. 9d, f) . Finally, we observed a pyridoxal-dependent reduction of nine IFN-induced genes in LPS-challenged MEFs that stably express SHMT2ΔN, but saw no change in MEFs in which a PLP-resistant mutant was expressed (Fig. 4f ). IL10 was upregulated by 2.1-fold in pyridoxal-supplemented SHMT2ΔN cells (Fig. 4f) but not in LPS-stimulated MEFs containing wild-type Abraxas 2, which suggests that IL10 is not directly dependent on BRISC-SHMT2 (Extended Data Fig 9a) . These experiments provide further evidence that PLP binding to SHMT2 regulates the BRISC-SHMT2 interaction and immune signalling in cells.
Endogenous small-molecule ligands that control ubiquitin signalling could be physiologically important. The influence of PLP on BRISC activity establishes a regulatory precedent for DUBs, akin to the plant hormone auxin and the second messenger inositol hexakisphosphate, which together allosterically regulate the activity of E3 ubiquitin ligases 26 . Post-translational modifications of the PLP acceptor-lysine 27,28 could provide additional layers of regulation of BRISC-SHMT2 association and immune signalling. It is possible that natural and synthetic SHMT2 binders-such as folate and PLP analogues-can modulate dimeric SHMT2 availability or conformation, and thus interferon signalling (Extended Data Fig. 10 ). Understanding the regulatory mechanisms of BRISC-SHMT2 interactions may therefore be useful for unlocking the potential of small-molecule ligands as therapeutic agents.
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MEthodS
No statistical methods were used to predetermine sample size. The experiments were not randomized and investigators were not blinded to allocation during experiments and outcome assessment. Cloning, protein expression and purification of BRISC-SHMT2 complex and SHMT1. Genes for the four-subunit human BRISC were cloned in the MultiBac system used for co-expression of multiprotein complexes in insect cells (Sf9) 29 . A single 6×His purification tag followed by a cleavable TEV site was engineered at the N terminus of BRCC45. Virus preparation, protein production and protein purification were performed as previously described 13 .
Wild-type and mutant forms of human SHMT2ΔN (residues 18-504) and SHMT1 were cloned in a pProEx-HTb vector and expressed in Escherichia coli BL21 (DE3) codon plus RIL in Terrific Broth (TB) in the presence of 100 μg/ml ampicillin and 34 μg/ml chloramphenicol at 37 °C to an optical density at 600 nm (OD 600 ) of 1.0-1.2 arbitrary units (AU). Cells were then induced with 0.5 mM isopropyl-1-thio-d-galactopyranoside (IPTG) and incubated overnight at 18 °C. Cells were collected by centrifugation at 5,500g and cell pellets were resuspended in lysis buffer (50 mM Tris-HCl, pH 7.6, 300 mM NaCl, 20 mM imidazole, 0.075% β-mercaptoethanol, 5% glycerol, 1 mM benzamidine, 0.8 mM phenylmethyl sulfonyl fluoride (PMSF) and 0.3 mg/ml lysozyme). Cells were lysed by sonication (1-s on, 3-s off for a total of 16 min) on ice and the lysates were cleared by centrifugation at 26,000g. The clarified lysate was loaded onto a 5-ml chelating FastFlow column (GE Healthcare), charged with Ni
2+
. The column was washed with 4 column volumes (CV) of wash buffer consisting of 50 mM Tris-HCl (pH 7.6), 500 mM NaCl, 20 mM imidazole, 0.075% β-mercaptoethanol and 1 mM benzamidine, and the protein was eluted by applying an imidazole gradient with elution buffer consisting of 50 mM Tris-HCl (pH 7.6), 300 mM NaCl, 300 mM imidazole, 0.075% β-mercaptoethanol and 1 mM benzamidine. The fractions containing SHMT2ΔN or SHMT1 were pooled and dialysed against buffer containing 20 mM MES, pH 6.5, 250 mM NaCl, 5% glycerol, 20 mM imidazole, 0.075% β-mercaptoethanol and 1 mM benzamidine. TEV was added to the protein sample and incubated overnight at 4 °C. Dialysed protein was loaded on a 16/600 Superdex200 column (GE Healthcare), equilibrated with 20 mM MES (pH 6.5), 500 mM NaCl and 2 mM TCEP.
BRISCΔNΔC and SHMT2ΔN(A285T) were mixed in vitro at 1:4 molar ratio and incubated on ice for 40 min. The mixture was then injected onto a Superdex 10/300 S200 column and peak fractions were analysed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Fractions containing the BRISCΔNΔC-SHMT2ΔN(A285T) complex were pooled, and the BRISC-SHMT2ΔN(A285T) complex was used immediately for grid preparation and electron microscopy analysis, as described below. The remaining BRISC-SHMT2ΔN(A285T) complex was pooled and stored at -80 °C at a final concentration of 0.5 mg/ml. Denatured and native masses of all protein preparations were verified by mass spectrometry. Negative-stain electron microscopy. BRISCΔNΔC and BRISCΔNΔC-SHMT2ΔN(A285T) complexes were diluted in buffer (25 mM HEPES, pH 7.5, 150 mM NaCl, 1 mM TCEP) to 0.0041 mg/ml and 0.0051 mg/ml, respectively, immediately before grid preparation. Glow-discharged, 300-mesh carbon-coated copper grids (Agar Scientific) were incubated with 7 μl BRISCΔNΔC or BRISCΔNΔC-SHMT2ΔN(A285T) for 60 s, passed through 3 droplets of water and stained twice with 2% w/v uranyl acetate for 20 s and 10 s, respectively. Excess liquid was removed by blotting. Micrographs were collected on an FEI Tecnai F20 electron microscope operated at 120 kV equipped with an FEI Ceta CMOS camera. Data processing was carried out using RELION 2.1. Initially, ~1,500 particles were picked manually and extracted with a 450 Å 2 box size. Particles were subjected to reference-free 2D classification to generate initial references for auto-picking. A total of 28,566 and 26,824 particles were picked for the BRISCNΔC and BRISCΔNΔC-SHMT2ΔN(A285T) complexes, respectively. One round of reference-free 2D classification was then carried out for each. Cryo-grid preparation and data collection. BRISCΔNΔC-SHMT2ΔN(A285T) complex was diluted to 0.05 mg/ml in buffer (25 mM HEPES, pH 7.5, 150 mM NaCl, 1 mM TCEP) immediately before grid preparation. Cryo-EM grids were prepared by placing 3 μl of this complex onto glow-discharged, 200-mesh copper grids (Quantifoil R1.2/1.3), followed by immediate blotting and plunge-freezing in liquid ethane cooled by liquid nitrogen, using an FEI Vitrobot IV at 95% relative humidity, chamber temperature of 4 °C. Datasets were collected on an FEI Titan Krios transmission electron microscope at 300 kV, using a total electron dose between 83 and 95 e -per Å 2 , a magnification of 75,000× and a final calibrated object sampling of 1.065 Å per pixel. Three independent datasets, giving a total of 7,494 movies, were recorded using the EPU automated acquisition software on an FEI Falcon III direct electron detector 30 . Each exposure movie had a total exposure time of 2 s collected over 70-79 frames with an electron dose of 1.2 e -per A 2 per frame. Detailed information on data collection is shown in Extended Data Table 1 . Image processing. A schematic of the data processing pipeline is shown in Extended Data Fig. 4 . Image processing was carried out using RELION 3.0 31 .
Drift-corrected averages of each movie were created using MOTIONCORR2 32 and the contrast transfer function of each determined using gCTF 33 . Initially, ~2,000 particles for each dataset were manually picked, extracted with a box size of 373 Å 2 and subjected to reference-free 2D classification to generate initial references for auto-picking. After auto-picking, each dataset was individually subjected to iterative rounds of reference-free 2D classification. Based on visual inspection, quality 2D average classes were selected for each dataset and then the three sets were combined. An initial model generated ab initio from the 2D class averages of the BRISCΔNΔC-SHMT2 negative-stain data, filtered to ~60 Å, was used for initial 3D classification of the combined dataset. Of the eight classes generated, one contained particles comprising the intact complex-that is, the BRCC36-Abraxas 2-SHMT2 core and both BRCC45-MERIT40 arms. This class was processed as a separate dataset consisting of 71,262 particles, representing the complete, two-arm structure. In parallel, this class-along with four others (totalling 514,930 particles)-was processed to represent the complete dataset. Both were subjected to a final round of 3D classification to remove any remaining 'bad' particles. The best classes from 3D classification were taken forward and subjected to 3D refinement, per-particle CTF correction and particle polishing 31 . C2 symmetry was imposed to the two-arm dataset. Post-processing was used to appropriately mask the model, estimate and correct for the B-factor of the maps. Final resolutions were determined using the gold-standard Fourier shell correlation criterion (FSC = 0.143). Local resolution was estimated using the local resolution feature in RELION.
Model building and refinement. A preliminary model for the BRISCΔNΔC-SHMT2ΔN(A285T) complex was generated using a combination of known crystal structures (BRCC36-Abraxas 2 superdimer from Camponotus floridanus (PDB code 5CW3) and human SHMT2 dimer (PDB code 6DK3)) and homology models generated by Phyre2 34 (BRCC45, consisting of two UEV domains, and MERIT40). This initial model was manually fitted into the electron microscopy density map for the C1 reconstruction (3.8 Å) using rigid-body fitting in UCSF Chimera 35 . The model was then manually fitted and rebuilt in COOT 36 to trace the human sequences of BRCC36 and Abraxas 2. Amino acid residues that lacked unambiguous density were deleted or modelled up to their Cβ position while preserving sequence information. The Cα backbone for BRCC45 UEV-N and UEV-M was traced into the remaining density mainly as alanine and glycine residues, and the precise sequence for BRCC45 could not be modelled with confidence. Gaps numbered arbitrarily were left where direct connectivity between secondary structure elements could not be determined.
The higher-resolution C1 map was used for model building and the two-arm model was generated by using the two-fold symmetry of the superdimer core.
The model was refined against the C1 and C2 maps in Phenix 37 using default parameters and secondary structure restraints. The overall quality of the model was assessed using MolProbity 38 . Fitting of the remaining BRCC45 UEV-C and MERIT40 domains into the peripheral parts of the C2 electron microscopy map was carried out using rigid-body fitting in Chimera; these are displayed for relative position and size comparison purposes only. DUB activity assays. BRISC complexes were assayed at 30 °C in DUB reaction buffer containing 50 mM HEPES-NaOH pH 7.0, 100 mM NaCl, 0.1 mg/ml BSA, 1 mM DTT and 0.005% Tween-20. Internally quenched fluorescent (IQF) K63-linked diUb (Lifesensors, catalogue number: DU6303) was used as a reporter for DUB activity (1 part IQF diUB to 9 parts unlabelled K63-linked diUb, prepared as previously described 39 ). Twenty-microlitre enzyme reactions were carried out in 384-well black flat-bottom low-flange plates (Corning; 35373). Cleaved diUb was monitored by measuring fluorescence intensity (excitation, 540 nm; emission, 580 nm; dichroic mirror, 560 nm) every 1 min over 20 min, and initial velocity (v o ) was calculated as the slope of the linear part of the reaction-progress curve. Fluorescence intensity units were converted to nM product concentration using TAMRA-labelled ubiquitin (Lifesensors, catalogue number: SI270T) as a standard. Enzyme concentrations for which a reasonable progress curve was obtained over 20 min were: 1 nM BRISC and 40 nM ARISC. Substrate concentration was 300 nM. IC 50 values were calculated by fitting the data using the GraphPad Prism built-in dose-response equation for inhibition with variable slope:
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x h ((log(IC ) ) ) 50 . Michaelis-Menten analysis in the absence and presence of increasing concentrations of SHMT2 was performed in DUB buffer containing 50 mM HEPES-NaOH (pH 6.8), 100 mM NaCl and 5 mM DTT. BRISC concentration was 1.5-2.0 nM and IQF K63-linked diUb was used (0-4 μM) as substrate (concentrations greater than 4 μM inhibited BRISC activity). Data were fit using the standard Michaelis-Menten equation, constraining V max to be less than the V max in the absence of SHMT2. Lineweaver-Burk plots and Michaelis-Menten analysis were performed using GraphPad Prism.
K63-linked hexaUb chains were also used to determine DUB activity. Sixty-microlitre reactions were carried out in 1.5 ml Eppendorf tubes at 30 °C in DUB reaction buffer. BRISC was incubated in the presence or absence of SHMT2ΔN or SHMT1 forms for 30 min at room temperature, before the addition of hexaUb(K63). Reactions containing 0.5 nM BRISC, 2 μM SHMT and 1 μM hexaUb(K63) were incubated for 1 h. Immunoblotting was performed with commercially available HRP-conjugated antibody to Ub (P4D1, Santa Cruz). SHMT2 PLP association and enzyme activity assays. PLP association assays were performed in 20-μl reactions in 384-well plates (Greiner) in buffer containing 50 mM HEPES-Na (pH 7.8), 50 mM NaCl, 50 mM KCl, 5% glycerol, 0.2 mM DTT, 0.1 mM EDTA and 0.005% Tween-20. SHMT2ΔN and point mutants (5 μM) were rapidly mixed with PLP (100 μM) and the reaction was monitored by measuring absorbance at 435 nm (every 30 s over 1 h) using a Hidex Sense microplate reader.
SHMT2ΔN enzyme activity was monitored in 20-μl reactions in 384-well, UV-transparent plates (Greiner). The synthetic substrate l-threo-phenylserine (2S,3R)-2-amino-3-hydroxy-3-phenylpropionic acid (BACHEM) was used as previously described 40 with minor modifications. Reactions were performed in buffer containing 50 mM HEPES-Na (pH 7.5), 100 mM NaCl, 0.5 mM TCEP and 0.005% Tween-20. SHMT2ΔN and point mutants (2 μM) were preincubated with 200 μM PLP for 1 h at 25 °C. Five microlitres of enzyme-PLP solution was added to 15 μl of solution containing 0-260 mM l-threo-phenylserine, and the reaction was monitored by measuring absorbance of benzyldehyde at 279 nm in a Hidex Sense microplate reader (every 2 min over 20 min). Absorbance units were converted to molar concentrations using a standard curve of known concentrations of benzyldehyde solutions (Sigma). Initial velocity (v o ) was calculated as the slope of the linear part of the reaction progress curve (20 min). Differential scanning fluorimetry. Thermal-shift assays were performed using an Applied Biosystems StepOnePlus Real-Time PCR instrument and a standardized differential scanning fluorimetry procedure 41 . Proteins were diluted in 50 mM TrisHCl (pH 7.4) and 100 mM NaCl to a concentration of 5 μM, and then incubated with the indicated concentration of compound in a total reaction volume of 10 μl, with final concentration of 2% (v/v) DMSO. SYPRO Orange (Invitrogen) was used as a fluorescence probe. The temperature was raised in regular 0.3-°C intervals from 25 °C to 95 °C. Compound binding experiments were assessed in duplicate and reported relative to DMSO controls. Normalized data were processed using the Boltzmann equation to generate sigmoidal denaturation curves, and T m /ΔT m values were calculated as previously described 41 . Native mass spectrometry. BRISCΔNΔC-SHMT2ΔN(A285T) (2.6 μM) and SHMT2ΔN and various mutants (2-20 μM) were buffer-exchanged into 0.2-1 M ammonium acetate (pH 7.2) using Zeba Spin 7K MWCO desalting columns (ThermoFisher). Samples were analysed by nano-electrospray ionization mass spectrometry using either a quadrupole-IMS-orthogonal time-of-flight (TOF) mass spectrometer (Synapt HDMS, Waters UK), operated as previously described 42 , or a quadrupole orbitrap mass spectrometer modified for transmission of high m/z ions (Q-Exactive Plus, ThermoScientific), operated as previously described 43, 44 . Both used gold-and palladium-coated nanospray tips prepared in-house. Data from the Synapt were processed using the MassLynx v4.1 suite of software supplied with the mass spectrometer, and UniDec v2.7.1 45 . Data from the Q-Exactive Plus were processed using Xcalibur Qual Browser v4.0.27.19 and UniDec v2.7.1. Analytical size-exclusion chromatography. Full-length BRISC and SHMT2ΔN or SHMT1 forms were mixed in vitro at 1:1 molar ratio (~6 μM) and incubated on ice for 30 min. The mixture was then injected onto a 2.4-ml Superose 6 analytical size-exclusion column. Peak fractions were analysed by SDS-PAGE. Controls for each protein were also run. Immunoprecipitation and immunoblots. All immunoprecipitations were performed as previously described 46 . In brief, BRCC36-and Abraxas 2-expressing cells were lysed in NETN 150 (0.5% NP40, 25 mM Tris pH 7.5, 150 mM NaCl, 0.5 mM EDTA with 1mM PMSF). Flag immunoprecipitations were performed on lysate supernatants for 4 h with agarose-conjugated anti-Flag M2 beads (Sigma) before elution in 0.1 mM glycine (pH 2.5). Immunoblots were performed with the following rabbit polyclonal antibodies at 1:1,000 dilution that were generated to recombinant proteins: MERIT40, Abraxas 2, BRCC36 and BRCC45. Commercially available antibodies to the HA epitope (HA.11 Covance) and SHMT2 (Cell Signaling) were used according to the manufacturer's directions. An Abraxas 2 deletion mutant (DM1) was used as control, as previously described 12 .
For assessment of IFNAR1 ubiquitylation in cells, cells were lysed in buffer containing 2% SDS, 150 mM NaCl, 10 mM Tris-HCl, pH 8.0, 50 mM sodium fluoride, 10mM N-ethylmaleimide and protease inhibitors. After boiling for 10 min, cell lysates were further diluted in immunoprecipiation buffer (10 mM Tris-HCl, pH 8.0, 150 mM NaCl, 2 mM EDTA, 1% Triton X-100). IFNAR1 was immunoprecipitated with a corresponding antibody (Bethyl Laboratories A304-290A). Resulting samples were separated by SDS-PAGE and analysed by immunoblotting using the anti-ubiquitin antibody (Lifesensor, VU101). Response to HSV infection, LPS and IFNβ. HSV lacking the ICP0 gene was used to infect cells at a multiplicity of infection of 0.1 for 2 h. Medium was then changed followed by a 5-h incubation period. Cells were then lysed in NETN150 and lysates were run on a 4-12% gradient SDS-PAGE gel for immunoblot. Phosphorylated STAT1 and STAT1 antibodies were purchased from Cell Signaling Corporation and used according to the manufacturer's specifications. Monitoring of phosphorylated STAT1 after LPS or IFNβ treatment was performed using conditions similar to those previously described 12 . Cellular PLP level manipulation and validation. MEFs or HEK293T cells were cultured in B6 vitamer-free Dulbecco's modified Eagle's medium (DMEM, from Gibco), B6-vitamer-free DMEM + 20 μmol/l pyridoxal hydrochloride (Sigma) or B6-vitamer-free DMEM + 50 μmol/l pyridoxal hydrochloride. All medium was supplemented with 10% FBS. After 48 h of culture, cells were collected and snap-frozen in liquid nitrogen. Pyridoxal, pyridoxal phosphate and pyridoxine levels were measured using liquid chromatography-mass spectrometry as previously described 47 .
qRT-PCR analysis of gene expression in MEFs. IFN-type I-related gene expression was analysed in Abraxas2 -/-MEFs after treatment with LPS or vehicle control. Gene expression was performed in Abraxas2 −/− MEFs and compared to derivative lines that had been stably reconstituted with Abraxas 2 wild type or mutant E144R using retroviral transduction. Following 16 h of LPS exposure, cells were directly lysed in TRIzol (Thermo Fisher Scientific) and RNA was extracted using Quick-RNA Miniprep Kit (Zymo Research) as per the manufacturer's instructions. Four hundred nanograms of eluted RNA was converted to cDNA using RT2 First Strand Kit (Qiagen). Next, the cDNA was mixed with RT2 SYBR Green Mastermix (Qiagen). The mouse IFN I RT2 Profiler PCR Array (Qiagen cat. no. PAMM-016Z) was performed and relative expression determined using the ∆∆C t method and normalized for four housekeeping genes according to manufacturer's guidance. Single measurements of three biological repeats were performed. Total results were analysed and compared to the gene signature of Abraxas2 -/-MEFs, with and without LPS treatment. Gene-expression analysis of MEFs cultured in B6-vitamer-free DMEM with and without 20 μM pyridoxal hydrochloride was performed as above. Reporting summary. Further information on research design is available in the Nature Research Reporting Summary linked to this paper.
Data availability
Coordinates have been deposited in the Protein Data Bank, code 6R8F. Cryo-EM reconstructions in C1 and C2 have been deposited in the Electron Microscopy Data Bank, codes EMD-4759 and EMD-4760. Any other relevant data are available from the corresponding authors upon reasonable request. BRCC36-Abraxas 2 superdimer, highlighting differences and similarities. The connectivity of the MPN -domain of Abraxas 2 and α4 helix by a crossover loop is different in the insect and human complexes, and is coloured orange in the latter structure. e, Superimposition of the BRCC36 MPN + domain from the insect (grey) and human (blue, green) heterodimers. Abraxas 2 regions with notable differences between the two structures are coloured orange.
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Extended Data Fig. 6 | Analysis of SHMT1 interaction with BRISC. a, Elution profile of wild-type SHMT1 from an S75 16/600 size-exclusion chromatography column (data are representative of two independent experiments). b, Elution profile of SHMT1 containing mutated residues designed to break the tetrameric interface (left; data are from a single experiment). Structure of SHMT1 tetramer (PDB code 1RV4), highlighting residues that are important for tetramerization (right). c, BRISC DUB activity against a fluorogenic K63-linked diUb substrate in the presence of the indicated forms of SHMT1 and SHMT2. Data are mean ± s.e.m. of three independent experiments carried out in duplicate. 
Extended Data Fig. 7 | Purification and analysis of SHMT2 mutants. a, Elution profile of the indicated forms of SHMT2ΔN from an S75 10/300 size-exclusion chromatography column (single experiment). b, Coomassie-stained SDS-PAGE analysis of the indicated SHMT2ΔN protein preparations (data are representative of two independent experiments). c, BRISC DUB activity against a fluorogenic K63-linked diUb substrate in the presence of the indicated SHMT2ΔN mutants. Data are mean ± s.e.m. of three independent experiments carried out in duplicate. d, BRISC DUB activity against K63-linked hexaUb chains in the presence of the different forms of SHMT2ΔN, or SHMT1. e, Ubiquitylation levels of IFNAR1 after IFNα stimulation in HEK293T cells that overexpress the indicated forms of Abraxas 2 and SHMT2ΔN. The annotation 'LL->RR' denotes SHMT2ΔN(L211R/L215R). IFNAR1 immunoprecipitation (IP) was performed under denaturing conditions and ubiquitin levels were detected using the vu-1 antibody. Mock IP was performed using a generic rabbit IgG antibody. f, Immunoprecipitation (IP) performed using anti-Flag antibody in MEFs that were transiently transfected with Flag-HA epitope-tagged SHMT2ΔN or mutants. Immunoblot was performed for Abraxas 2 and SHMT2, as indicated. UTF, untransfected cells (used as control). g, MEFs that overexpress the indicated SHMT2ΔN or mutants were challenged with LPS, and interferon-receptor-dependent signal transduction response was assessed by immunoblot for STAT1 phosphorylated at Y701. Data shown in d, e are representative of three independent experiments. For gel source data, see Supplementary Fig. 1 .
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Statistical parameters
When statistical analyses are reported, confirm that the following items are present in the relevant location (e.g. figure legend, table legend, main text, or Methods section).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted 
Software and code
Policy information about availability of computer code
Data collection
Cryo-EM data were collected using ThermoFisher (previously FEI) EPU software. Negative stained data were collected using ThermoFisher (previously FEI) TEM imaging and analysis (TIA).
Data analysis -Cryo-EM data and structural models were analysed using: Chimera (1.11.2), COOT (0.8.6), Phenix (1.11.1_2575), Relion (3.0), CCP4 (7.0), ResMap (1.1.4), MotionCorr2, gCTF (0.5), Pymol (1.8.6.0). -Mass spectrometry data was analysed using the following software: MassLynx v4.1, UniDec v2.7.1, Xcalibur Qual Browser v4.0.27.19.
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
